Ascend Capital’s Regenxbio RGNX Stock Holding History

Ascend Capital’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-163,299	Closed	-$5.43M	–	261
2017 Q4	$5.43M	Sell	163,299 -180,988	-53%	-$5.45M	0.2%	114
2017 Q3	$11.3M	Buy	344,287 +57,299	+20%	+$1.29M	0.43%	73
2017 Q2	$5.67M	Buy	+286,988	New	+$5.56M	0.26%	101

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Ascend Capital's RGNX Position: Q1 2018 in Review

Ascend Capital sold out of Regenxbio (RGNX) in Q1 2018, closing a stake of 163,299 shares — an estimated $5.43M sold.

Ascend Capital first reported a position in RGNX in Q2 2017 and held it in 3 quarters. The position peaked at $11.3M in Q3 2017. 120 funds tracked by Wall St. Rank hold RGNX as of Q1 2018.

Ascend Capital reported no remaining Regenxbio position as of Q1 2018 after selling out during the quarter.
Ascend Capital sold 163,299 Regenxbio shares in Q1 2018, an estimated $5.43M.
Ascend Capital first reported a position in Regenxbio in Q2 2017 and held it in 3 quarters.
Ascend Capital's Regenxbio position peaked at $11.3M in Q3 2017.
120 funds tracked by Wall St. Rank held Regenxbio as of Q1 2018.

Based on Ascend Capital's 13F filing for Q1 2018, filed 14 May 2018.